PKD Breakthrough Shrinks Cysts, Enhances Kidney Health
Novel Targets for Polycystic Kidney Disease
Tags: Monash University, Australia, Healthcare & Lifesciences
The technology targets Polycystic Kidney Disease (PKD) with a novel approach by disrupting a cystogenic pathway through the elimination of Factor A or inhibition of Factor B, reducing renal cystogenesis. It demonstrates that genetic deletion of Factor A or chemical inhibition of Factor B can notably decrease cyst burden in PKD models. This innovation offers hope for treating PKD and related syndromes, with potential applications in significantly reducing kidney cysts and improving patient outcomes. A patent has been filed, and xCystence Bio is set to commercialize this breakthrough.
IP Type or Form Factor: Patent Pending; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Biotechnology; Healthcare Provider
